June 30 (Reuters) - Arcturus Therapeutics Holdings Inc ARCT.O:
ARCTURUS THERAPEUTICS ANNOUNCES POSITIVE INTERIM PHASE 2 MULTIPLE DOSE DATA FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY PROGRAM
ARCTURUS THERAPEUTICS HOLDINGS INC - ARCT-810 SAFE AND WELL TOLERATED AT ALL DOSE LEVELS
ARCTURUS THERAPEUTICS HOLDINGS INC - ARCT-810 REDUCES GLUTAMINE TO NORMAL LEVELS
Source text: ID:nBw4CNfDra
Further company coverage: ARCT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.